The extension granted by Nasdaq provides Moleculin Biotech with additional time to meet the bid price requirement, which could potentially prevent a delisting. This could stabilize the stock in the short term as it reduces immediate pressure on the company. However, the long-term impact will depend on the company's ability to meet the requirement within the extended period.